Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tubingen, Wilhelmstraβe 27, D-72074 Tübingen, Germany; Germany; German Centre for Infection Research (DZIF), Partner Site Tübingen, Germany; Département de Biochimie et de Biologie Cellulaire, Faculté des Sciences et Techniques, Université d'Abomey-Calavi, Cotonou, Benin.
Centre de Recherches Médicales de Lambaréné, BP: 242 Lambaréné, Gabon.
Vaccine. 2020 Jun 2;38(27):4263-4272. doi: 10.1016/j.vaccine.2020.04.046. Epub 2020 May 5.
Despite appreciable immunogenicity in malaria-naive populations, many candidate malaria vaccines are considerably less immunogenic in malaria-exposed populations. This could reflect induction of immune regulatory mechanisms involving Human Leukocyte Antigen G (HLA-G), regulatory T (Treg), and regulatory B (Breg) cells. Here, we addressed the question whether there is correlation between these immune regulatory pathways and both plasmablast frequencies and vaccine-specific IgG concentrations.
Fifty Gabonese adults with lifelong exposure to Plasmodium spp were randomized to receive three doses of either 30 µg or 100 µg GMZ2-CAF01, or 100 µg GMZ2-alum, or control vaccine (rabies vaccine) at 4-week intervals. Only plasma and peripheral blood mononuclear cells isolated from blood samples collected before (D0) and 28 days after the third vaccination (D84) of 35 participants were used to measure sHLA-G levels and anti-GMZ2 IgG concentrations, and to quantify Treg, Breg and plasmablast cells. Vaccine efficacy was assessed using controlled human malaria infection (CHMI) by direct venous inoculation of Plasmodium falciparum sporozoites (PfSPZ Challenge).
The sHLA-G concentration increased from D0 to D84 in all GMZ2 vaccinated participants and in the control group, whereas Treg frequencies increased only in those receiving 30 µg or 100 µg GMZ2-CAF01. The sHLA-G level on D84 was associated with a decrease of the anti-GMZ2 IgG concentration, whereas Treg frequencies on D0 or on D84, and Breg frequency on D84 were associated with lower plasmablast frequencies. Importantly, having a D84:D0 ratio of sHLA-G above the median was associated with an increased risk of P. falciparum infection after sporozoites injection.
Regulatory immune responses are induced following immunization. Stronger sHLA-G and Treg immune responses may suppress vaccine induced immune responses, and the magnitude of the sHLA-G response increased the risk of Plasmodium falciparum infection after CHMI. These findings could have implications for the design and testing of malaria vaccine candidates in semi-immune individuals.
尽管在无疟疾人群中具有可观的免疫原性,但许多候选疟疾疫苗在暴露于疟疾的人群中的免疫原性要低得多。这可能反映了诱导涉及人类白细胞抗原 G(HLA-G)、调节性 T(Treg)和调节性 B(Breg)细胞的免疫调节机制。在这里,我们研究了这些免疫调节途径与浆母细胞频率和疫苗特异性 IgG 浓度之间是否存在相关性的问题。
50 名在一生中都接触过疟原虫的加蓬成年人被随机分为三组,分别接受 30μg 或 100μg GMZ2-CAF01,或 100μg GMZ2-铝佐剂,或狂犬病疫苗(对照疫苗),间隔 4 周进行 3 次接种。仅使用来自 35 名参与者的血液样本在第三次接种(D84)前(D0)和第 28 天(D84)收集的血浆和外周血单核细胞来测量 sHLA-G 水平和抗-GMZ2 IgG 浓度,并定量 Treg、Breg 和浆母细胞。通过直接静脉接种恶性疟原虫孢子(PfSPZ Challenge)来评估疫苗的功效。
在所有接受 GMZ2 疫苗接种的参与者和对照组中,sHLA-G 浓度从 D0 增加到 D84,而 Treg 频率仅在接受 30μg 或 100μg GMZ2-CAF01 的参与者中增加。D84 时的 sHLA-G 水平与抗-GMZ2 IgG 浓度降低相关,而 D0 或 D84 时的 Treg 频率和 D84 时的 Breg 频率与浆母细胞频率降低相关。重要的是,D84:D0 sHLA-G 比值高于中位数与 PfSPZ 注射后感染恶性疟原虫的风险增加相关。
免疫后诱导调节性免疫反应。更强的 sHLA-G 和 Treg 免疫反应可能会抑制疫苗诱导的免疫反应,而 sHLA-G 反应的幅度增加了 PfSPZ 接种后感染恶性疟原虫的风险。这些发现可能对在半免疫个体中设计和测试疟疾候选疫苗具有重要意义。